Treatment for underdiagnosed cause of debilitating chest pain

December 17, 2018

PHILADELPHIA - Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if scans came back clear, with no signs of blocked coronary arteries. Some of these cases are caused by a little-known phenomenon called coronary slow flow. Now, researchers at Jefferson (Philadelphia University + Thomas Jefferson University), have demonstrated for the first time a simple technique to effectively treat this under-recognized condition. They published their findings in the Journal of Invasive Cardiology on December 15.

"One of the biggest issues with coronary slow flow is that many cardiologists aren't familiar with it and don't know what to look for to diagnose it," said senior author Michael Savage, MD, Director of the Cardiac Catheterization Lab at the Sidney Kimmel Medical College at Thomas Jefferson University. "Here we've shown that once you do recognize it, the condition can be treated with an existing and safe medical intervention that reverses the problem."

Not a lot is known about the coronary slow flow. It is identified by angiogram of the heart, revealing arteries that fill with blood more slowly than normal, even in the absence of fatty plaque deposits. But what causes the condition, and why in 80 percent of cases patients experience additional episodes of chest pain, is still unknown. One association that can be drawn, says first author Hetal H. Mehta, MD, a cardiology fellow at Jefferson, is that smokers are two-to-three times more likely to experience the phenomenon.

When Dr. Savage and others first saw the condition on angiograms of their patients, it appeared similar to the no-reflow phenomenon caused by microvascular spasm during coronary angioplasty procedures. Since that condition could be treated with a drug called nicardipine, Dr. Savage and colleagues decided to test it with their coronary slow flow patients. "It worked incredibly well," he said.

In this study, the researchers analyzed the data and outcomes of 30 patients with coronary slow flow who were treated during cardiac catheterization with an intracoronary injection of nicardipine . They found a total of 49 blood vessels with slow blood flow. After treatment with nicardipine, all of the vessels showed normalized blood flow.

"These results suggest that microvascular spasm may be responsible for this condition, which can be effectively reversed with a calcium channel blocker like nicardipine," said Dr. Savage. "It's a simple intervention that takes only a few seconds to administer, and helps diagnose the condition and treat it at the same time."

Nicardipine appears to reverse the condition in the short term, but future studies are needed to explore whether the one-time treatment reverses the condition permanently, or whether patients would benefit from long-term use of an oral calcium channel blocker.
-end-
The authors report no conflicts of interest.

Article reference: Hetal H. Mehta, Mackenzie Morris, David L. Fischman, John J. Finley, Nicholas Ruggiero, Paul Walinsky, Melissa McCarey, Michael P. Savage, "The Spontaneous Coronary Slow-Flow Phenomenon: Reversal by Intracoronary Nicardipine," Journal of Interventional Cardiology, Dec 15, 2018.

Media Contact: Edyta Zielinska, edyta.zielinska@jefferson.edu, 215-955-7359.

Thomas Jefferson University

Related Chest Pain Articles from Brightsurf:

New approach helps EMTs better assess chest pain en route to hospital
A study conducted at Wake Forest Baptist Health shows that on-scene use of a new protocol and advanced diagnostic equipment can help paramedics better identify patients at high risk for adverse cardiac events.

Brain activity during psychological stress may predict chest pain in people with heart disease
The brain's reaction to stress could be an important indicator of angina (chest pain) among people with known heart disease.

Chest pain, stress tests warrant attention even if arteries are clear
Patients who experience chest pain and have abnormal results on a cardiac stress test but who do not have blocked arteries often experience changes in their symptoms and stress test results over time, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Women carry heavier burden of chest pain, but less artery narrowing
Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia) have significantly more chest pain caused by plaque build-up, yet less extensive disease as compared with men, according to new research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

More isn't better when it comes to evaluating chest pain
New and more effective tests are needed to help predict heart attacks and other major cardiac events in patients with chest pain, the second most common reason for emergency department visits in the US.

Artificial intelligence could prevent unneeded tests in patients with stable chest pain
Artificial intelligence (AI) could prevent unnecessary diagnostic tests in patients with stable chest pain, according to research presented today at ICNC 2019.

Kaiser Permanente improves emergency care for patients with chest pain
Emergency physicians at Kaiser Permanente hospitals in Southern California reduced hospital admissions and cardiac stress testing by using new criteria to assess the level of risk patients with chest pain have for subsequent cardiac events.

Treatment for underdiagnosed cause of debilitating chest pain
Researchers find an effective way to treat an underdiagnosed condition that can cause heart attack and heart-attack-like symptoms.

Diagnostic protocol effective in identifying ED patients with acute chest pain
A relatively new accelerated diagnostic protocol is effective in identifying emergency department patients with acute chest pain who can be safely sent home without being hospitalized or undergoing comprehensive cardiac testing, according to researchers at Wake Forest Baptist Medical Center.

Chest pain drug falls short in preventing first episode of ventricular arrhythmia or death
A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine (used to treat chest pain; brand name Ranexa®) was safe but didn't decrease the likelihood of the first occurrence of ventricular arrhythmias or death in this high-risk population.

Read More: Chest Pain News and Chest Pain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.